Botensilimab,balstilimab
agenus
[]
rapid abstract session: bot+bal in pmmr/mss mcrc. orr 23%, durable responses. exciting data, colitis/diarrhea rate 21% grade 3-4 with 1-2mg/kg anti-ctla4. #gi23 
Medical Oncologist, GI cancers @nki_nl neoadjuvant #immunotherapy #cancerresearch. Opinions my own